Cryopreservation Medium with Optimized DMSO and HSA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell cryopreservation media, particularly those using DMSO, pose challenges in maintaining cell viability and safety due to toxicity concerns, and there is a need for a medium that effectively protects cells during cryopreservation while minimizing DMSO concentration.
Innovation Solution
A cryopreservation medium comprising DMSO, human serum albumin (HSA), and a base solution such as phosphate buffered saline or CryoStor® CS5, CS2, and CS10, with optimized concentrations of DMSO (1.0% to 6.0% w/v) and HSA (1.0% to 6.0% w/v), is developed to enhance cell protection and safety during cryopreservation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DMSO is used as cryoprotectant at high concentration, then cryoprotective function is improved, but cell toxicity increases
Solution Approach 1:
The patent optimizes the DMSO concentration parameter to a specific range (1.0%-6.0% w/v) to achieve the best balance between cryoprotective effect and cell toxicity. This parameter optimization resolves the contradiction by finding the optimal value that provides sufficient protection while minimizing harmful effects.
Solution Approach 2:
The patent creates a composite cryopreservation medium containing DMSO combined with human serum albumin (HSA) at optimized concentrations. This composite formulation enhances the overall cryoprotective effect while the HSA component helps mitigate the cytotoxicity of DMSO, thus resolving the contradiction between protection and toxicity.
2Object-affected harmful factors
If DMSO concentration is reduced, then cell toxicity is minimized, but cryoprotective effect deteriorates
Solution Approach 1:
The patent formulates a composite medium where DMSO is combined with human serum albumin (HSA). This composite approach allows reduction of DMSO concentration to minimize toxicity while the HSA component compensates for the reduced cryoprotective effect, maintaining overall protection efficacy.
Solution Approach 2:
Human serum albumin acts as an intermediary substance that enhances the overall cryoprotective effect of the medium. It works synergistically with reduced DMSO concentrations to maintain cell protection while minimizing toxicity, effectively bridging the gap between reduced DMSO and maintained protective function.
3Reliability
If optimized DMSO concentration (1.0%-6.0% w/v) is used, then cell viability is improved, but formulation complexity increases
Solution Approach 1:
The patent establishes a clear, quantifiable concentration range (1.0%-6.0% w/v) for DMSO and corresponding HSA concentrations. This parameter specification simplifies the formulation process by providing explicit guidelines, reducing complexity while ensuring optimal cell viability through standardized preparation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The medium significantly improves cell viability and reduces toxicity, maintaining high cell viability after recovery and expansion, while minimizing DMSO-related cytotoxicity, thus ensuring effective cryopreservation for clinical applications.
Implementation Method 1
Dimethyl sulfoxide (DMSO) is currently the best cell cryopreservation protectant
Implementation Method 2
the preservation and cryogenic transportation of cell products are facing great challenges
Data Source
AI summary
The present application relates to the field of cell biology. The present application provides a cryopreservation medium for cryogenic storage of a biological sample, particularly a cryopreservation medium for cryogenic storage of cells in an apheresis sample.